| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1745 | Desmethyl Mk-6884 | Precursor for PET imaging 11C-radiolabeled MK-6884 |
|
| DCC1746 | Desmethyldiazepam | Primary metabolite of diazepam, binding to the GABA A receptor benzodiazepine modulatory site |
|
| DCC1747 | Desmethyl-hd-800 | PET precursor of preparing radiolabel [11C]HD-800, a high affinity brain penetrant PET tracer for imaging microtubules |
|
| DCC1748 | Desthiobiotin Polyethyleneoxide Iodoacetamide | Cysteine reactive protein labeling agent |
|
| DCC1749 | Dexamethasone 21-phosphate Disodium | Pro-drug of dexamethasone, anti-inflammatory glucocorticoid, stimulating glutamine uptake in the cerebral cortex |
|
| DCC1750 | Dexamethasone Beloxil | Glucocorticoid, Anti-inflammatory Agent |
|
| DCC1751 | Dexloxiglumide | Cholecystokinin antagonist, selective for the CCKA subtype |
|
| DCC1752 | Dexmethylphenidate Hydrochloride | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
|
| DCC1753 | Dezocine | Natural modulator of mu-, delta-, and kappa-opioid receptors |
|
| DCC1754 | Df-1012 | 5-HT3 Receptor antagonist; Antitussive; Anti-inflammatory; Antiasthmatic |
|
| DCC1755 | Df-461 | Potent Squalene Synthase Inhibitor |
|
| DCC1756 | Dfk167 | Cell-permeable, reversible and selective inhibitor of ɣ-secretase |
|
| DCC1757 | Dfkbp-2 | Proteolysis targeting chimeras (PROTAC), potently decreasing FKBP12 abundance in MV4;11 cells, leading to over 80% reduction of FKBP12 at 0.1 μM and 50% reduction at 0.01 μM |
|
| DCC1758 | Dg-051 | Novel potent, orally active inhibitor of LTA4H |
|
| DCC1759 | dgat2 Inhibitor 122 | Selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2) |
|
| DCC1760 | Dg-c8-phip | The major adduct formed by the food-borne carcinogen, PhIP with DNA |
|
| DCC1761 | Dgj-pfpht | Novel human α-galactosidase A ligand, capable of stabilizing α-Gal A and restoring trafficking |
|
| DCC1762 | Dgts(16:0/16:0) | Abundant lipid in the membranes of many algae, lower plants, and fungi, showing an inverse concentration relationship with phosphatidylcholine, being capable of replacing phosphatidylcholine |
|
| DCC1763 | Dgy-08-097 | Novel HCV NS3 degrader, reducing susceptibility to resistance mutations, potently inhibiting HCV in a cellular infection model, exhibiting the most potent degradation (DC50 of 50nM at 4h) of HCV NS3, |
|
| DCC1764 | Dh20931 | Novel growth inhibitor of both triple-positive and triple-negative human breast cancer cell lines |
|
| DCC1765 | Dha-37 | Novel inducer of autophagic cell death through upregulation of HMGB1 in A549 cells |
|
| DCC1766 | Dhpcc-9 | Novel Pim kinase inhibitor |
|
| DCC1767 | Dhpm-93 | The most potent inhibitor of sodium iodide symporter (NIS) reported to date |
|
| DCC1768 | Di-1859 | Novel potent, selective and covalent inhibitor of DCN1, selectively inhibiting neddylation of cullin 3 in cells |
|
| DCC1769 | Diabzi Sting Agonist | Novel STING agonist with enhanced binding to STING and cellular function, displaying strong anti-tumour activity |
|
| DCC1770 | Diabzi Sting Agonist-3 | Novel potent and selective STING agonist, activating secretion of IFNβ, IL-6, TNF, and KC/GROα, exhibiting durable anti-tumour effects |
|
| DCC1771 | Diafluo | Novel probe for protein S-sulfinylation from cells |
|
| DCC1772 | Dianicline | Selective alpha4beta2 nAChR partial agonist for the treatment of nicotine dependence to assist in smoking cessation |
|
| DCC1773 | Diazaborine | Novel Inhibitor of the AAA-ATPase Drg1, blocking ribosome biogenesis |
|
| DCC1774 | Diazoline | Histamine H1-receptor antagonist |
|
